Objective  To investigate the efficacy of Tangganjian pills combined with semaglutide in patients suffering from type 2 diabetes associated with obesity and to assess its effects on intestinal mucosal barrier function as well as serum kisspeptin levels.

Methods  Patients with type 2 diabetes and obesity who visited Wuhan Hospital of Traditional Chinese Medicine from January to December 2023 were selected and divided into the control group and the observation group randomly. The control group was treated with semaglutide, while the observation group was treated with Tangganjian pills combined with semaglutide, with 3 months courses treatment. The overall effective rate and incidence of adverse reactions, obesity index and blood glucose index [waist-hip ratio (WHR), body mass index (BMI), fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), glycated hemoglobin (HbA1c)], intestinal mucosal barrier function[the diamine oxidase (DAO), D-lactate acid (DLC), and lipopolysaccharide (LPS)], level of serum kisspeptin were compared between the two groups.

Results  A total of 80 patients were included, with 40 in each of the two groups. The overall effective rate of the observation group was 90.00%, significantly higher than the 70.00% of the control group (P<0.05). After treatment, the WHR, BMI, FPG, 2hPG, HbA1c, DAO, DLC, LPS and the level of serum kisspeptin in both groups decreased significantly than before (P<0.05). Moreover, all indicators in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion  Tangganjian pill combined with semaglutide in treating patients with type 2 diabetes and obesity is more effective than treatment with semaglutide alone, it can regulate the intestinal mucosal barrier function, and reduce the serum kisspeptin level, with high safety.

1.郭梦佳, 熊怡, 陶思路, 等. 2型糖尿病合并颈动脉斑块患病率及影响因素的Meta分析[J]. 数理医药学杂志, 2025, 38(1): 39-50. [Guo MJ, Xiong Y, Tao SL, et al. The prevalence and influencing factors of carotid plaque complicated with type 2 diabetes mellitus: a Meta-analysis[J]. Journal of Mathematical Medicine, 2025, 38(1): 39-50.] DOI: 10.12173/j.issn.1004-4337.202409168.

2.张紫涵, 张晓桀, 杨瑀泽, 等. 基于蛋白质组学方法探讨沙蓬粗寡糖改善2型糖尿病肝损伤的作用机制[J]. 药学前沿, 2025, 29(8): 1261-1270. [Zhang ZH, Zhang XJ, Yang YZ, et al. Mechanism of agiophyllum oligo saccharides in improving type 2 diabetes mellitus related liver injury based on proteomics method[J]. Frontiers in Pharmaceutical Sciences, 2025, 29(8): 1261-1270.] DOI: 10.12173/j.issn.2097-4922.202503028.

3.魏秀秀, 苟筱雯, 赵林华, 等. 态靶辨证在肝胃郁热型肥胖2型糖尿病中的运用-大柴胡汤加黄连、知母、赤芍 [J]. 辽宁中医杂志, 2020, 47(3): 1-3. [Wei XX, Gou XW, Zhao LH, et al. Application of "State-Target" strategy in obesity type 2 diabetes with heat stagnation syndrome in liver and stomach--Major Bupleurum decoction with Huanglian (Coptidis rhizoma), Zhimu (Anemarrhena rhizome) and Chishao (Paeoniae radix Rubra) [J]. Liaoning Journal of Traditional Chinese Medicine, 2020, 47(3): 1-3.] DOI: 10.13192/j.issn.1000-1719.2020.03.001.

4.冯颖, 苏衍进, 司海龙, 等. 水陆地黄汤联合盐酸贝那普利对气阴两虚夹察型糖尿病肾病氧化应激及临床指标的影响 [J]. 陕西中医, 2020, 41(5): 605-608. [Feng Y, Su YJ, Si HL, et al. Effects of Shuilu Dihuang decoction combined with benazepril hydrochloride on oxidative stress and clinical indicators in type 2 diabetic nephropathy with deficiency of both qi and Yin and blood stasis[J]. Shaanxi Journal of Traditional Chinese Medicine, 2020, 41(5): 605-608.] DOI: 10.3969/j.issn.1000-7369.2020.05.014.

5.蔡宏桂, 姚南珍, 李思韵, 等. 茵陈五苓散联合利拉鲁肽对肥胖型2型糖尿病患者糖脂代谢、胰岛素敏感性和氧化应激的影响[J]. 现代生物医学进展, 2024, 24(1): 162-166. [Cai HG, Yao NZ, Li SY, et al. Effects of Yinchen Wuling powder and liraglutide on glucose and lipid metabolism,insulin sensitivity and oxidative stress in obese type 2 diabetes patients[J]. Progress in Modern Biomedicine, 2024, 24(1): 162-166.] DOI:  10.3760/cma.j.issn.1674-5809.2019.05.006.

6.李孟英, 王德满. 肥胖型2型糖尿病内科治疗研究进展 [J]. 社区医学杂志, 2020, 18(7): 549-552. [Li MY, Wang DM. Research progress on medical treatment of obese type 2 diabetes mellitus[J]. Journal of Community Medicine, 2020, 18(7): 549-552.] DOI: 10.19790/j.cnki.JCM.2020.07.21.

7.韩美芬, 赵彬, 陈伟, 等. 司美格鲁肽在治疗肥胖症中的作用机制及临床应用进展[J]. 中国新药杂志, 2022, 31(9): 859-862. [Han MF, Zhao B, Chen W. The mechanism and clinical application of semaglutide in obesity[J]. Chinese Journal of New Drugs, 2022, 31(9): 859-862.] DOI: 10.3969/j.issn.1003-3734.2022.09.008.

8.雷珍珍, 张文想, 梁艳, 等. 司美格鲁肽注射液不良反应的文献分析[J]. 实用药物与临床, 2024, 27(8): 584-588. [Lei ZZ, Zhang WX, Liang Y, et al. Literature analysis of adverse reactions of semaglutide injection[J]. Practical Pharmacy and Clinical Remedies, 2024, 27(8): 584-588.] DOI: 10.14053/j.cnki.ppcr.202408004.

9.吴莹, 张义生, 范彦博. 糖肝煎浓缩丸水提部分的提取工艺研究[J]. 中国药师, 2016, 19(7): 1236-1238. [Wu Y, Zhang YS, Fan YB, et al. Study on extraction technology for water extract of tangganjian concentrated pills[J]. China Pharmacist, 2016, 19(7): 1236-1238.] DOI: 10.3969/j.issn.1008-049X.2016.07.003.

10.胡丽娟, 万婧, 朱浩. 糖肝煎丸联合腹部推拿对二甲双胍治疗肥胖2型糖尿病患者糖脂代谢和炎症因子的影响[J]. 中国药师, 2024, 27(4): 595-602. [Hu LJ, Wan J, Zhu H. Effect of Tanganjianwan combined with abdominal massage on glucose and lipid metabolism and inflammatory factors in patients of metformin treatment with obesity and type 2 diabetes mellitus[J]. China Pharmacist, 2024, 27(4): 595-602.] DOI: 10.12173/j.issn.1008-049X.202403094.

11.曾晓语. 糖肝煎丸治疗肝郁脾虚、湿热内蕴型2型糖尿病的临床研究[D]. 武汉: 湖北中医药大学, 2019.

12.Mruk MH, Kulaszyńska M, Czarnecka W, et al. Insights into the mechanisms of action of Akkermansia muciniphila in the treatment of non-communicable diseases[J]. Nutrients, 2024, 16(11): 1695-1696. DOI: 10.3390/nu16111695.

13.苏小优, 万燕, 陈超超, 等. 肠脂肪酸结合蛋白在肠黏膜屏障损伤相关疾病中的作用研究进展[J]. 海南医学院学报, 2024, 30(12): 939-946. [Su XY, Wan Y, Chen CC, et al. Research progress on the role of intestinal fatty acid binding proteins in diseases associated with intestinal mucosal barrier damage[J]. Journal of Hainan Medical University, 2024, 30(12): 939-946.] DOI: 10.13210/j.cnki.jhmu.temp.20231126.002.

14.张晓娟, 张洁, 娄萍萍, 等. 维格列汀联合二甲双胍治疗初诊2型糖尿病伴腹型肥胖患者的疗效及对血清kisspeptin的影响[J]. 药物评价研究, 2022, 45(7): 1355-1360. [Zhang XJ, Zhang J, Lou PP, et al. Efficacy of vigliptin combined with metformin in treatment of newly diagnosed abdominal obesity type 2 diabetes mellitus and its effect on serum level of kisspeptin[J]. Drug Evaluation Research, 2022, 45(7): 1355-1360.] DOI: 10.7501/j.issn.1674-6376.2022.07.017.

15.中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2013年版）[J]. 中国医学前沿杂志, 2015, 7(3): 26-89. [Diabetes Branch of Chinese Medical Association. Guidelines for prevention and treatment of type 2 diabetes in China (2013 edition)[J]. Chinese Journal of the Frontiers of Medical Science, 2015, 7(3): 26-89.] DOI: 10.3760/cma.j.issn.1000-6699.2014.10.020.

16.郑筱萸, 主编. 中药新药临床研究指导原则（试行）[M]. 北京: 中国医药科技出版社, 2002: 233-237.

17.李春生, 主编. 现代肥胖病学[M]. 北京: 科学技术文献出版社, 2004: 518-524.

18.中华中医药学会糖尿病基层防治专家指导委员会. 国家糖尿基层中医防治管理指南（2022）[J]. 中华糖尿病杂志, 2023, 15(2): 100-117. [Expert Steering Committee for Primary Prevention and Treatment of Diabetes Mellitus of Chinese Medical Association. National guidelines for prevention and treatment of diabetes mellitus in primary Chinese medicine (2022)[J]. Chinese Journal of Diabetes, 2023, 15(2): 100-117.] DOI: 10.13288/j.11-2166/r.2022.24.017.

19.贺兰芝, 周鹏翔, 黄淑琳, 等. 司美格鲁肽和度拉糖肽治疗2型糖尿病的疗效与安全性比较: 基于倾向性评分匹配的回顾性队列研究[J]. 药物流行病学杂志, 2024, 33(6): 601-611. [He LZ, Zhou PX, Huang SL, et al. Comparison of the effectiveness and safety of semaglutide versusdulaglutide for treating type 2 diabetes: a retrospective cohortstudy utilizing propensity score matching[J]. Chinese Joumnal of Pharmacoepidemiology, 2024, 33(6): 601-611.] DOI: 10.12173/j.issn.1005-0698.202401055.

20.何思颐, 邹锟, 杨楠, 等. 中国公立医院2型糖尿病防治指南的实施效果: 一项使用A-GIST工具的横断面研究[J]. 医学新知, 2025, 35(6): 611-621. [He SY, Zou K, Yang N, et al. Implementation effect of the clinical practice guideline for type 2diabetes mellitus in public hospitals in China: a cross-sectional study using the A-GIST tool[J]. Yi Xue Xin Zhi, 2025, 35(6): 611-621.] DOI: 10.12173/j.issn.1004-5511.202502076.

21.徐瑞颜, 成金燕, 李乐愚. 复方番石榴合剂治疗超重肥胖型2型糖尿病疗效及对患者肠黏膜屏障功能的影响[J]. 陕西中医, 2022, 43(8): 1045-1048. [Xu RY, Cheng JY, Li LY. Effects of compound Fanshiliu mixture on clinical efficacy and intestinal mucosal barrier function in patients with overweight-obesity complicated with type 2 diabetes mellitus[J]. Shaanxi Journal of Traditional Chinese Medicine, 2022, 43(8): 1045-1048.] DOI: 10.3969/i.issn.1000-7369.2022.08.013.

22.孙倩, 谭伟. 司美格鲁肽治疗肥胖型2型糖尿病的研究进展[J]. 中国现代医生, 2022, 60(29): 117-120. [Sun Q, Tan W. Research progress of smegliptide in the treatment of obese type 2 diabetes mellitus[J]. Modern Chinese Doctor, 2022, 60(29): 117-120.] https://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI1MTIyNDE1NDU1NRIWendranpsbWwteXl3czIwMjIyOTAyNxoIeXVicjN3Nnk%3D.

23.王文琦, 张涛. 司美格鲁肽对2型糖尿病合并冠心病患者心肌缺血总负荷及血清炎症因子的影响[J]. 临床荟萃, 2022, 37(11): 996-1000. [Wang WQ, Zhang T. Effect of semaglutide on total myocardial ischemic burden and serum inflammatory factors in patients with type 2 diabetes mellitus complicated with coronary heart disease[J]. Clinical Focus, 2022, 37(11): 996-1000.] DOI: 10.3969/j.issn.1004-583X.2022.11.006.

24.黄玲, 倪冲, 彭智, 等. 司美格鲁肽联合格列齐特治疗2型糖尿病并慢性心力衰竭临床评价[J]. 中国药业, 2023, 32(6): 93-95. [Huang L, Ni C, Peng Z, et al. Clinical evaluation of semaglutide combined with gliclazide in the treatment of type 2 diabetes mellitus with chronic heart failure[J]. China Pharmaceuticals, 2023, 32(6): 93-95.] DOI: 10.3969/i.issn.1006-4931.2023.06.023.

25.张跃飞, 张旭, 许文娟. 司美格鲁肽联合二甲双胍治疗糖尿病的临床效果分析[J]. 糖尿病新世界, 2023, 26(12): 97-100. [Zhang YF, Zhang X, Xu WJ. Clinical effect analysis of semaglutide combined with metformin in the treatment of diabetes mellitus[J]. Diabetes New World Magazine, 2023, 26(12): 97-100.] D01: 10.16658/i.cnki.1672-4062.2023.12.097.

26.何志伟, 张义生, 范彦博, 等. 初探糖肝煎浓缩丸对2型糖尿病合并非酒精性脂肪肝大鼠的治疗作用[J]. 中国医院药学杂志, 2018, 38(7): 737-741. [He ZW, Zhang YS, Fan YB, et al. Preliminary investigation on therapeutic effects of Tangganjian concentrated pills in rats with type 2 diabetes mellitus and nonalcoholic fatty liver[J]. Chinese Journal of Hospital Pharmacy, 2018, 38(7): 737-741.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.07.11.

27.吴莹. 糖肝煎浓缩丸的制备工艺与质量标准研究[D]. 武汉: 湖北中医药大学, 2017.

28.Zhang X, Zhao YW, Zhang MH, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats[J]. PLoS One, 2012, 7(8): e42529-e42529. DOI: 10.1371/journal.pone.0042529.

29.柴思佳, 邓翀, 董媛媛. 南五味子对2型糖尿病大鼠肝脏保护作用的研究[J]. 中南药学, 2014, 12(8): 758-761. [Chai SJ, Deng C, Dong YY. Protective effect of Schisandra sphenanthera on the liver in type-2 diabetic rats[J]. Central South Pharmacy, 2014, 12(8): 758-761.] DOI: 10.7539/j.issn.1672-2981.2014.08.010.

30.Tolson KP, Garcia C, Yen S, et al. Impaired kisspeptin signaling decreases metabolism and promotes glucose intolerance and obesity[J]. J Clin Invest, 2014, 124(7): 3075-3079. DOI: 10.1172/JCI71075.